Skip to main content
Top
Published in: BMC Nephrology 1/2016

Open Access 01-12-2016 | Case report

Acute interstitial nephritis due to flecainide therapy in the 38th week of pregnancy

Authors: Julius J. Schmidt, Leyla Ramazan, Clemens Bockemeyer, Hans-Heinrich Günter, Jens Martens-Lobenhoffer, Tina Ganzenmüller, Stefanie M. Bode-Böger, Jan T. Kielstein

Published in: BMC Nephrology | Issue 1/2016

Login to get access

Abstract

Background

Acute interstitial nephritis (AIN) represents a frequent cause of acute kidney injury. While many etiologies of AIN have been recognized, the majority (60–70 %) are due to allergic reactions or drug exposure. Many different classes of drugs and several agents within a class can cause drug induced AIN. Flecainide, a class Ic antiarrhythmic drug, had thus far not been associated with the occurrence of AIN.

Case presentation

Here we describe a case of biopsy proven AIN after flecainide therapy in a pregnant patient. The 24-year old Caucasian woman was admitted to our university hospital for a planned c-section. She had been put on flecainide at a dose of 200 mg/d for supraventricular tachyarrhythmia of the fetus ten days earlier. The only fleaainide drug level was obtained 24 h after the last dose. At this time point the serum level was still in the therapeutic range (392 ng/mL). After hospital admission the patient underwent uneventful c-section and delivered a 3095 g baby girl with mild insufficiency of the tricuspid valve. In the hours following the c-section, a single dose of the non-steroidal anti-inflammatory drug (NSAID) ibuprofen (600 mg) as well as single dose of diclofenac (100 mg) was administered. Within 5 days after c-section her baseline creatinine of 30 μmol/L increased to 277 μmol/L. The serum creatinine continued to rise to 411 μmol/L on hospital day # 7. On renal ultrasound kidneys were enlarged and swollen. Urinary sediment at this point only revealed slight proteinuria (506 mg/g creatinine). A renal biopsy was performed showing acute interstitial nephritis. Within four days the renal function improved after discontinuation of flecainide and NSAIDs even without steroid therapy and the patient was discharged with a creatinine of 88 μmol/L after 13 days in the hospital.

Conclusion

This case suggests that flecainide, at least in combination with NSAIDs, can cause AIN.
Literature
4.
go back to reference Haefeli WE, Bargetzi MJ, Follath F, Meyer UA. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol. 1990;15:776–9.CrossRefPubMed Haefeli WE, Bargetzi MJ, Follath F, Meyer UA. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol. 1990;15:776–9.CrossRefPubMed
5.
go back to reference Winkelmann BR, Leinberger H. Life-threatening flecainide toxicity. A pharmacodynamic approach. Ann Intern Med. 1987;106:807–14.CrossRefPubMed Winkelmann BR, Leinberger H. Life-threatening flecainide toxicity. A pharmacodynamic approach. Ann Intern Med. 1987;106:807–14.CrossRefPubMed
6.
go back to reference Meurin P, Larrazet F, Weber H, Bourmayan C. Iatrogenic acute renal failure caused by overdosage of flecainide acetate. Presse Med. 1998;27:1473–5.PubMed Meurin P, Larrazet F, Weber H, Bourmayan C. Iatrogenic acute renal failure caused by overdosage of flecainide acetate. Presse Med. 1998;27:1473–5.PubMed
7.
go back to reference Koppel C, Oberdisse U, Heinemeyer G. Clinical course and outcome in class IC antiarrhythmic overdose. J Toxicol Clin Toxicol. 1990;28:433–44.CrossRefPubMed Koppel C, Oberdisse U, Heinemeyer G. Clinical course and outcome in class IC antiarrhythmic overdose. J Toxicol Clin Toxicol. 1990;28:433–44.CrossRefPubMed
Metadata
Title
Acute interstitial nephritis due to flecainide therapy in the 38th week of pregnancy
Authors
Julius J. Schmidt
Leyla Ramazan
Clemens Bockemeyer
Hans-Heinrich Günter
Jens Martens-Lobenhoffer
Tina Ganzenmüller
Stefanie M. Bode-Böger
Jan T. Kielstein
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2016
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-016-0240-8

Other articles of this Issue 1/2016

BMC Nephrology 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.